KALA BIO, Inc. (KALA) NASDAQ

1.07

+0.14(+15.14%)

Updated at December 04 12:13PM

Currency In USD

KALA BIO, Inc.

Address

1167 Massachusetts Avenue

Arlington, MA 02476

United States of America

Phone

781 996 5252

Sector

Healthcare

Industry

Biotechnology

Employees

38

First IPO Date

July 20, 2017

Key Executives

NameTitlePayYear Born
Dr. R. Kim Brazzell Ph.D.Head of R&D and Chief Medical Officer703,6441953
Mr. Todd BazemorePrincipal Executive Officer & Director732,5071970
Mr. Vincent KosewskiSenior Vice President of Manufacturing & Supply Chain Management01963
Dr. Justin Hanes Ph.D.Founder & Chair of the Scientific Advisory Board0N/A
Ms. Mary Reumuth CPAChief Financial Officer, Treasurer & Secretary01975
Ms. Jill S. SteierExecutive Director of Investor Relations & Corporate Communications0N/A
Dr. Francis S. Mah M.D.Chief Medical Advisor0N/A
Mr. Darius Kharabi J.D., M.B.A.Chief Business Officer01980
Mr. Josiah CraverSenior Vice President & Corporate Controller0N/A
Mr. Carl RennieExecutive Director of Account Management0N/A

Description

Kala Bio, Inc. is a biopharmaceutical company. It focuses on the development and commercialization of therapeutics using proprietary nanoparticle-based mucus penetrating particles with an initial focus on the treatment of eye diseases. The company was founded by Justin Hanes, Robert S. Langer and Colin R. Gardner in 2009 and is headquartered in Arlington, MA.